Assessing the clinical characteristics and management of COVID-19 among pediatric patients in Ghana : findings and implications

Show simple item record

dc.contributor.author Sefah, Israel
dc.contributor.author Sarkodie, Seth Adade
dc.contributor.author Pichierri, Giuseppe
dc.contributor.author Schellack, Natalie
dc.contributor.author Godman, Brian
dc.date.accessioned 2023-09-27T07:55:02Z
dc.date.available 2023-09-27T07:55:02Z
dc.date.issued 2023-02
dc.description SUPPLEMENTARY MATERIAL : TABLE S1: Study Questionnaire. en_US
dc.description DATA AVAILABILITY STATEMENT : Additional data are available from the corresponding authors on reasonable request. en_US
dc.description.abstract There is an increasing focus across countries on researching the management of children admitted to hospital with COVID-19. This stems from an increasing prevalence due to new variants, combined with concerns with the overuse of antimicrobials driving up resistance rates. Standard treatment guidelines (STGs) have been produced in Ghana to improve their care. Consequently, there is a need to document the clinical characteristics of children diagnosed and admitted with COVID-19 to our hospital in Ghana, factors influencing compliance to the STG and treatment outcomes. In all, 201 patients were surveyed between March 2020 and December 2021, with males accounting for 51.7% of surveyed children. Those aged between 6 and 10 years were the largest group (44.8%). Nasal congestion and fever were some of the commonest presenting complaints, while pneumonia was the commonest (80.6%) COVID-19 complication. In all, 80.0% of all admissions were discharged with no untreated complications, with a 10.9% mortality rate. A combination of azithromycin and hydroxychloroquine (41.29%) was the most prescribed antimicrobial regimen. Compliance to the STG was variable (68.2% compliance). Increased compliance was associated with a sore throat as a presenting symptom. Mortality increased following transfer to the ICU. However, current recommendations to prescribe antimicrobials without demonstrable bacterial or fungal infections needs changing to reduce future resistance. These are areas to address in the future. en_US
dc.description.department Pharmacology en_US
dc.description.uri https://www.mdpi.com/journal/antibiotics en_US
dc.identifier.citation Sefah, I.A.; Sarkodie, S.A.; Pichierri, G.; Schellack, N.; Godman, B. Assessing the Clinical Characteristics and Management of COVID-19 among Pediatric Patients in Ghana: Findings and Implications. Antibiotics 2023, 12, 283. https://doi.org/10.3390/antibiotics12020283. en_US
dc.identifier.issn 2079-6382 (print)
dc.identifier.other 10.3390/antibiotics12020283
dc.identifier.uri http://hdl.handle.net/2263/92432
dc.language.iso en en_US
dc.publisher MDPI en_US
dc.rights © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). en_US
dc.subject Antimicrobials en_US
dc.subject Children en_US
dc.subject Ghana en_US
dc.subject Guidelines en_US
dc.subject Hospitals en_US
dc.subject Outcomes en_US
dc.subject COVID-19 pandemic en_US
dc.subject Coronavirus disease 2019 (COVID-19) en_US
dc.subject SDG-03: Good health and well-being en_US
dc.subject Standard treatment guidelines (STGs) en_US
dc.title Assessing the clinical characteristics and management of COVID-19 among pediatric patients in Ghana : findings and implications en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record